Spironolactone Prevents Na +/H + Exchange Enhancement in Primary Aldosteronism
The study was undertaken to determine the possible effect of an aldosterone antagonist, spironolactone (SP), on red blood cell sodium-hydrogen exchange (NHE) enhancement in primary aldosteronism (PA) and essential hypertension (EH). NHE was measured as the amiloride-inhibited fraction of H + efflux...
Gespeichert in:
| Veröffentlicht in: | American journal of hypertension 1997-03, Vol.10 (3), p.341-345, Article 341 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 345 |
|---|---|
| container_issue | 3 |
| container_start_page | 341 |
| container_title | American journal of hypertension |
| container_volume | 10 |
| creator | Koren, Wladimir Koldanov, Robert Postnov, Ilya Yu Postnov, Yuvenaly V. |
| description | The study was undertaken to determine the possible effect of an aldosterone antagonist, spironolactone (SP), on red blood cell sodium-hydrogen exchange (NHE) enhancement in primary aldosteronism (PA) and essential hypertension (EH). NHE was measured as the amiloride-inhibited fraction of H
+ efflux (V
max) from erythrocytes (pH
i 6.40 ± 0.05) into a Na
+-containing medium (pH
o 8.00 ± 0.05). Subjects were 12 hypertensive patients with aldosterone-producing adrenal adenoma (six treated with 200 mg/day spironolactone for an least 5 days and six drug-free), 20 essential hypertensives (10 treated with the same regimen of spironolactone and 10 drug-free), and 20 healthy controls. Treatment with spironolactone decreased NHE in PA patients but did not change the mean NHE in essential hypertensives. It is concluded that SP may be useful to differentiate between elevated NHE in PA and essential hypertension. |
| doi_str_mv | 10.1016/S0895-7061(96)00394-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78855458</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0895706196003949</els_id><sourcerecordid>78855458</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-72491b73816b0037c97f23827c48e1e9e04823d335f615e5ac0afab178a813083</originalsourceid><addsrcrecordid>eNqFkc9rFDEUx4Moda3-CYU5iVLGJpvfeJBS1m6hjEJtkb2EbOaNRmcma5It9b8321n24KWnd_j-eI_PQ-iE4A8EE3F2g5XmtcSCvNPiPcZUs1o_QzOipK6Jxvw5mh0sL9GrlH5hjJkQ5AgdFVkITWeoudn4GMbQW5fDCNXXCPcw5lQ1tjo9W1an1eLB_bTjD6gWY5kOhiJXfixOP9j4tzrv25AylBKfhtfoRWf7BG_28xjdfl58u1jW118ury7Or2vHGM-1nDNN1pIqItblcum07OZUzaVjCghowEzNaUsp7wThwK3DtrNrIpVVhGJFj9HbqXcTw58tpGwGnxz0vR0hbJORSnHO-M7IJ6OLIaUIndlMdxuCzY6jeeRodpCMFuaRo9Eld7JfsF0P0B5Se3BF__hfr_PZZh_GHK3vn2yvp7Qv5B4O5Tb-NkJSyc3y-8qwZrVqGqLMXfF_mvxQmN57iCY5D-UZrY_gsmmDf2LjP2V2opY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78855458</pqid></control><display><type>article</type><title>Spironolactone Prevents Na +/H + Exchange Enhancement in Primary Aldosteronism</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Koren, Wladimir ; Koldanov, Robert ; Postnov, Ilya Yu ; Postnov, Yuvenaly V.</creator><creatorcontrib>Koren, Wladimir ; Koldanov, Robert ; Postnov, Ilya Yu ; Postnov, Yuvenaly V.</creatorcontrib><description>The study was undertaken to determine the possible effect of an aldosterone antagonist, spironolactone (SP), on red blood cell sodium-hydrogen exchange (NHE) enhancement in primary aldosteronism (PA) and essential hypertension (EH). NHE was measured as the amiloride-inhibited fraction of H
+ efflux (V
max) from erythrocytes (pH
i 6.40 ± 0.05) into a Na
+-containing medium (pH
o 8.00 ± 0.05). Subjects were 12 hypertensive patients with aldosterone-producing adrenal adenoma (six treated with 200 mg/day spironolactone for an least 5 days and six drug-free), 20 essential hypertensives (10 treated with the same regimen of spironolactone and 10 drug-free), and 20 healthy controls. Treatment with spironolactone decreased NHE in PA patients but did not change the mean NHE in essential hypertensives. It is concluded that SP may be useful to differentiate between elevated NHE in PA and essential hypertension.</description><identifier>ISSN: 0895-7061</identifier><identifier>EISSN: 1879-1905</identifier><identifier>EISSN: 1941-7225</identifier><identifier>DOI: 10.1016/S0895-7061(96)00394-9</identifier><identifier>PMID: 9056693</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; aldosterone ; Blood Pressure - drug effects ; Blood Pressure - physiology ; Erythrocytes - drug effects ; Erythrocytes - metabolism ; essential hypertension ; Female ; Humans ; Hydrogen - blood ; Hydrogen - metabolism ; Hyperaldosteronism - metabolism ; Hypertension - metabolism ; Hypertension - physiopathology ; Male ; Middle Aged ; Mineralocorticoid Receptor Antagonists - pharmacology ; Na +/H + antiport ; primary aldosteronism ; red blood cells ; Renin - blood ; Sodium - blood ; Sodium - metabolism ; Sodium-Hydrogen Exchangers - metabolism ; spironolactone ; Spironolactone - pharmacology</subject><ispartof>American journal of hypertension, 1997-03, Vol.10 (3), p.341-345, Article 341</ispartof><rights>1997 Elsevier Science Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-72491b73816b0037c97f23827c48e1e9e04823d335f615e5ac0afab178a813083</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9056693$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koren, Wladimir</creatorcontrib><creatorcontrib>Koldanov, Robert</creatorcontrib><creatorcontrib>Postnov, Ilya Yu</creatorcontrib><creatorcontrib>Postnov, Yuvenaly V.</creatorcontrib><title>Spironolactone Prevents Na +/H + Exchange Enhancement in Primary Aldosteronism</title><title>American journal of hypertension</title><addtitle>AJH</addtitle><description>The study was undertaken to determine the possible effect of an aldosterone antagonist, spironolactone (SP), on red blood cell sodium-hydrogen exchange (NHE) enhancement in primary aldosteronism (PA) and essential hypertension (EH). NHE was measured as the amiloride-inhibited fraction of H
+ efflux (V
max) from erythrocytes (pH
i 6.40 ± 0.05) into a Na
+-containing medium (pH
o 8.00 ± 0.05). Subjects were 12 hypertensive patients with aldosterone-producing adrenal adenoma (six treated with 200 mg/day spironolactone for an least 5 days and six drug-free), 20 essential hypertensives (10 treated with the same regimen of spironolactone and 10 drug-free), and 20 healthy controls. Treatment with spironolactone decreased NHE in PA patients but did not change the mean NHE in essential hypertensives. It is concluded that SP may be useful to differentiate between elevated NHE in PA and essential hypertension.</description><subject>Adult</subject><subject>aldosterone</subject><subject>Blood Pressure - drug effects</subject><subject>Blood Pressure - physiology</subject><subject>Erythrocytes - drug effects</subject><subject>Erythrocytes - metabolism</subject><subject>essential hypertension</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrogen - blood</subject><subject>Hydrogen - metabolism</subject><subject>Hyperaldosteronism - metabolism</subject><subject>Hypertension - metabolism</subject><subject>Hypertension - physiopathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mineralocorticoid Receptor Antagonists - pharmacology</subject><subject>Na +/H + antiport</subject><subject>primary aldosteronism</subject><subject>red blood cells</subject><subject>Renin - blood</subject><subject>Sodium - blood</subject><subject>Sodium - metabolism</subject><subject>Sodium-Hydrogen Exchangers - metabolism</subject><subject>spironolactone</subject><subject>Spironolactone - pharmacology</subject><issn>0895-7061</issn><issn>1879-1905</issn><issn>1941-7225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9rFDEUx4Moda3-CYU5iVLGJpvfeJBS1m6hjEJtkb2EbOaNRmcma5It9b8321n24KWnd_j-eI_PQ-iE4A8EE3F2g5XmtcSCvNPiPcZUs1o_QzOipK6Jxvw5mh0sL9GrlH5hjJkQ5AgdFVkITWeoudn4GMbQW5fDCNXXCPcw5lQ1tjo9W1an1eLB_bTjD6gWY5kOhiJXfixOP9j4tzrv25AylBKfhtfoRWf7BG_28xjdfl58u1jW118ury7Or2vHGM-1nDNN1pIqItblcum07OZUzaVjCghowEzNaUsp7wThwK3DtrNrIpVVhGJFj9HbqXcTw58tpGwGnxz0vR0hbJORSnHO-M7IJ6OLIaUIndlMdxuCzY6jeeRodpCMFuaRo9Eld7JfsF0P0B5Se3BF__hfr_PZZh_GHK3vn2yvp7Qv5B4O5Tb-NkJSyc3y-8qwZrVqGqLMXfF_mvxQmN57iCY5D-UZrY_gsmmDf2LjP2V2opY</recordid><startdate>19970301</startdate><enddate>19970301</enddate><creator>Koren, Wladimir</creator><creator>Koldanov, Robert</creator><creator>Postnov, Ilya Yu</creator><creator>Postnov, Yuvenaly V.</creator><general>Elsevier Inc</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970301</creationdate><title>Spironolactone Prevents Na +/H + Exchange Enhancement in Primary Aldosteronism</title><author>Koren, Wladimir ; Koldanov, Robert ; Postnov, Ilya Yu ; Postnov, Yuvenaly V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-72491b73816b0037c97f23827c48e1e9e04823d335f615e5ac0afab178a813083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>aldosterone</topic><topic>Blood Pressure - drug effects</topic><topic>Blood Pressure - physiology</topic><topic>Erythrocytes - drug effects</topic><topic>Erythrocytes - metabolism</topic><topic>essential hypertension</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrogen - blood</topic><topic>Hydrogen - metabolism</topic><topic>Hyperaldosteronism - metabolism</topic><topic>Hypertension - metabolism</topic><topic>Hypertension - physiopathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mineralocorticoid Receptor Antagonists - pharmacology</topic><topic>Na +/H + antiport</topic><topic>primary aldosteronism</topic><topic>red blood cells</topic><topic>Renin - blood</topic><topic>Sodium - blood</topic><topic>Sodium - metabolism</topic><topic>Sodium-Hydrogen Exchangers - metabolism</topic><topic>spironolactone</topic><topic>Spironolactone - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koren, Wladimir</creatorcontrib><creatorcontrib>Koldanov, Robert</creatorcontrib><creatorcontrib>Postnov, Ilya Yu</creatorcontrib><creatorcontrib>Postnov, Yuvenaly V.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hypertension</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koren, Wladimir</au><au>Koldanov, Robert</au><au>Postnov, Ilya Yu</au><au>Postnov, Yuvenaly V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spironolactone Prevents Na +/H + Exchange Enhancement in Primary Aldosteronism</atitle><jtitle>American journal of hypertension</jtitle><addtitle>AJH</addtitle><date>1997-03-01</date><risdate>1997</risdate><volume>10</volume><issue>3</issue><spage>341</spage><epage>345</epage><pages>341-345</pages><artnum>341</artnum><issn>0895-7061</issn><eissn>1879-1905</eissn><eissn>1941-7225</eissn><abstract>The study was undertaken to determine the possible effect of an aldosterone antagonist, spironolactone (SP), on red blood cell sodium-hydrogen exchange (NHE) enhancement in primary aldosteronism (PA) and essential hypertension (EH). NHE was measured as the amiloride-inhibited fraction of H
+ efflux (V
max) from erythrocytes (pH
i 6.40 ± 0.05) into a Na
+-containing medium (pH
o 8.00 ± 0.05). Subjects were 12 hypertensive patients with aldosterone-producing adrenal adenoma (six treated with 200 mg/day spironolactone for an least 5 days and six drug-free), 20 essential hypertensives (10 treated with the same regimen of spironolactone and 10 drug-free), and 20 healthy controls. Treatment with spironolactone decreased NHE in PA patients but did not change the mean NHE in essential hypertensives. It is concluded that SP may be useful to differentiate between elevated NHE in PA and essential hypertension.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>9056693</pmid><doi>10.1016/S0895-7061(96)00394-9</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0895-7061 |
| ispartof | American journal of hypertension, 1997-03, Vol.10 (3), p.341-345, Article 341 |
| issn | 0895-7061 1879-1905 1941-7225 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78855458 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
| subjects | Adult aldosterone Blood Pressure - drug effects Blood Pressure - physiology Erythrocytes - drug effects Erythrocytes - metabolism essential hypertension Female Humans Hydrogen - blood Hydrogen - metabolism Hyperaldosteronism - metabolism Hypertension - metabolism Hypertension - physiopathology Male Middle Aged Mineralocorticoid Receptor Antagonists - pharmacology Na +/H + antiport primary aldosteronism red blood cells Renin - blood Sodium - blood Sodium - metabolism Sodium-Hydrogen Exchangers - metabolism spironolactone Spironolactone - pharmacology |
| title | Spironolactone Prevents Na +/H + Exchange Enhancement in Primary Aldosteronism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T00%3A28%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spironolactone%20Prevents%20Na%20+/H%20+%20Exchange%20Enhancement%20in%20Primary%20Aldosteronism&rft.jtitle=American%20journal%20of%20hypertension&rft.au=Koren,%20Wladimir&rft.date=1997-03-01&rft.volume=10&rft.issue=3&rft.spage=341&rft.epage=345&rft.pages=341-345&rft.artnum=341&rft.issn=0895-7061&rft.eissn=1879-1905&rft_id=info:doi/10.1016/S0895-7061(96)00394-9&rft_dat=%3Cproquest_cross%3E78855458%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78855458&rft_id=info:pmid/9056693&rft_els_id=S0895706196003949&rfr_iscdi=true |